Vivani Medical (NASDAQ:VANI) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Vivani Medical (NASDAQ:VANI) in a research report report published on Thursday,Benzinga reports. HC Wainwright currently has a $4.00 target price on the stock.

Vivani Medical Trading Up 2.8 %

Shares of NASDAQ:VANI opened at $1.09 on Thursday. The company has a market capitalization of $64.57 million, a PE ratio of -2.42 and a beta of 3.20. Vivani Medical has a twelve month low of $1.03 and a twelve month high of $2.22. The firm has a 50 day simple moving average of $1.16 and a 200-day simple moving average of $1.22.

Institutional Trading of Vivani Medical

Several institutional investors and hedge funds have recently bought and sold shares of VANI. Jane Street Group LLC purchased a new stake in Vivani Medical in the 4th quarter valued at $66,000. Wealthedge Investment Advisors LLC acquired a new stake in Vivani Medical in the 4th quarter valued at about $43,000. Geode Capital Management LLC lifted its holdings in Vivani Medical by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 342,891 shares of the company’s stock valued at $401,000 after purchasing an additional 15,008 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in Vivani Medical by 19.1% in the 4th quarter. Northern Trust Corp now owns 71,915 shares of the company’s stock valued at $83,000 after purchasing an additional 11,540 shares in the last quarter. Hedge funds and other institutional investors own 6.78% of the company’s stock.

About Vivani Medical

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.